Marbocyl

CONTRAINDICATIONS
Do not use in cases where the bacteria strains involved is resistant to other fluoroquinolones (cross resistance).
Do not administer to an animal previously found to be hypersensitive to marbofloxacin or other quinolone.

ADVERSE REACTIONS
Administration by the intramuscular route may cause transient local reactions such as pain and swelling at the injection site and inflammatory lesions which persist at least 12 days afterinjection.
However,in cattle, subcutaneous route was shown to be better tolerated locally than intramuscular route. Therefore, the subcutaneous route is recommended in heavy cattle. For the injections, the neck should be preferred in cattle.
No other undesirable effects have been observed in cattle.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

SPECIAL WARNINGS
Special warnings for target species
None.
Special precautions for use in animals
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing official and local antimicrobial policies should be taken into account when the product is used.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
Efficacy data have shown an insufficient efficacy of the product for the treatment of acute mastitis caused by Gram positive strains.
Special precautions to be taken by the person administering the medicinal product to animals
None.
Use during pregnancy and lactation
Studies in laboratory animals (rats ,rabbits) did not show any teratogenic, embryotoxic effects or any maternal toxicity of marbofloxacin.
Safety of the product at 2mg/kg has been shown in cows during gestation and in suckling calves when used in cows.
Safety of the product at 8mg/kg has not been determined in cows during gestation or in suckling calves when used in cows. Use only according to the benefit/risk assessment by the veterinarian.
In the case of use in the cow during lactation,see paragraph« Withdrawal Period»

Interaction with other medicinal products and other forms of interaction
None known

Overdose
No sign of overdosage has been observed after administration of 3 times there commended dose.
Overdosage may cause signs in the form of acute neurological disorders which would have to be treated symptomatically.

Incompatibilities
None known .

SPECIAL STORAGE PRECAUTIONS
Following withdrawal of the first dose,do not store above25°C.Protect from light.
After first opening: 28 days.
Keep out of the reach and sight of children.

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS ,IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed in accordance with local requirements.

FOR ANIMAL TREATMENT ONLY
TO BE SUPPLIED ONLY ON VETERINARY PRESCRIPTION